Image
 
Image
References:
  • 1.
    Elisa Dal Canto, et. al Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications, European Journal of Preventive
    Cardiology,Volume 26, Issue 2_suppl, 1 December 2019, Pages 25–32, https://doi.org/10.1177/2047487319878371
  • 2.
    Eeg-Olofsson K et al. Diabetologia. 2009 Jan;52(1):65-73.
  • 3.
    Shah AD et al. Lancet Diabetes Endocrinol 2015;3:105–113
  • 4.
    Gæde P et al. Diabetologia 2016;59:2298–2307.
  • 5.
    ADA,Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47
  • 6.
    Andersen A, Knop FK, Vilsbøll T. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs. 2021 Jun;81(9):1003-1030.
  • 7.
    Aroda VR, et al. Diabetes Care. 2019;42(9):1724-1732.
  • 8.
    Aroda VR, et al. Diabetes Obes Metab. 2022;24(7):1338-1350.
  • 9.
    Pratley R, et al. Lancet. 2019;394:39-50 16.
  • 10.
    Husain M, et al. N Engl J Med. 2019;381:841-851.
  • 11.
    Dahl K, et al. Diabetes Obes Metab. 2021;23(7):1594-1603.
  • 12.
    Yanai H, et al. Diabetes. Cardiol Res. 2022 Oct;13(5):303-308.
  • 13.
    Rosenstock JR et al. Presented at the 70th American College of Cardiology Annual Scientific Session, 15–17 May 2021.
  • 14.
    Borgharkar SS,BMJ Open Diabetes Res Care. 2019 Jul 14;7(1):e000654.
  • 15.
    Zinman B, et al. Diabetes Care. 2019;42(12):2262-2271.
  • 16.
    Rybelsus®. Prescribing information. Novo Nordisk. 2023.
  • 17.
    Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor
    agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. doi:10.3390/jcm12010145